Vivos Therapeutics Inc (VVOS) 13F Positioning & Ownership Changes (Q2 2026)

On August 20, 2026, Vivos Therapeutics (VVOS) put out a press release announcing the opening of a new testing and treatment facility, and filed this 8-K to pass that news along to investors. The filing itself is pretty bare-bones—it doesn't include the facility's location, cost, or any expected financial impact; those details would live in the attached press release (Exhibit 99.1). Since it was furnished under Item 7.01 (Regulation FD Disclosure), this is essentially a routine way of sharing a public announcement rather than a report of a major corporate event.

Vivos Therapeutics (VVOS) issued a press release on August 5, 2026, announcing that it was granted a new U.S. patent, number 12,697,190. The release was attached as Exhibit 99.1 to an 8-K and furnished under Item 7.01 (Regulation FD), which means it was provided for transparency rather than formally filed with the SEC.

AI summary pending

Vivos Therapeutics entered into a securities purchase agreement with two investors to raise $2.1 million. The company sold preferred stock and warrants at $0.582 per unit. About $1 million came from cash, and another $1 million came from converting a previous bridge loan. Warrants are exercisable at $0.456 per share for five years.

AI summary pending